Published in Front Microbiol on July 26, 2013
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Unfolded protein response in hepatitis C virus infection. Front Microbiol (2014) 0.92
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Animal models for the study of HCV. Curr Opin Virol (2015) 0.86
Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses (2016) 0.80
Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol (2015) 0.76
Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. J Clin Transl Hepatol (2015) 0.76
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. Annu Rev Genet (2015) 0.75
Hepatitis C: a mouse at the end of the tunnel. Cell Res (2013) 0.75
Proteomic approaches to analyzing hepatitis C virus biology. Proteomics (2015) 0.75
Animal model studies on viral infections. Front Microbiol (2014) 0.75
Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol (2016) 0.75
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res (2016) 0.75
A new HCV mouse model on the block. Cell Res (2014) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 10.61
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature (2011) 5.84
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature (2011) 5.28
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol (2007) 4.22
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol (2003) 4.06
Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet (1996) 4.00
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell (1991) 3.31
Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A (1995) 3.30
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 3.10
Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol (1998) 2.97
Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev (1993) 2.95
Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med (2005) 2.78
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet (1995) 2.62
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol (2004) 2.47
Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity (2007) 2.45
Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. J Virol (1995) 2.38
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology (2011) 2.24
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci U S A (2011) 2.14
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc Natl Acad Sci U S A (2013) 1.93
A critical role for the chimpanzee model in the study of hepatitis C. Hepatology (2004) 1.90
Replication of a hepatitis C virus replicon clone in mouse cells. Virol J (2006) 1.90
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Serology-enabled discovery of genetically diverse hepaciviruses in a new host. J Virol (2012) 1.80
Transgenic expression of human signal regulatory protein alpha in Rag2-/-gamma(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A (2011) 1.71
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci U S A (2007) 1.69
Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology (2013) 1.67
Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest (2010) 1.66
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med (2011) 1.66
Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology (2011) 1.64
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol (2010) 1.56
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther (2002) 1.51
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat (2012) 1.50
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev (2011) 1.47
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol (2004) 1.43
Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol (2011) 1.41
NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol (2008) 1.39
Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun (2006) 1.38
A novel immunodeficient mouse model--RAG2 x common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J Interferon Cytokine Res (1999) 1.38
HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology (2009) 1.38
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 1.38
Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proc Natl Acad Sci U S A (2011) 1.35
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. J Med Primatol (1988) 1.29
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Nonprimate hepaciviruses in domestic horses, United kingdom. Emerg Infect Dis (2012) 1.28
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology (2011) 1.23
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol (2010) 1.17
Animal models for hepatitis C. Curr Top Microbiol Immunol (2013) 1.17
Transmission of hepatitis C virus infection to tree shrews. Virology (1998) 1.14
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
The chimpanzee model of hepatitis C virus infections. ILAR J (2001) 1.13
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
The long and winding road leading to the identification of the hepatitis C virus. J Hepatol (2009) 1.12
Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest (2002) 1.11
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog (2006) 1.09
The origin of hepatitis C virus. Curr Top Microbiol Immunol (2013) 1.07
Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood (2013) 1.07
Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J Gen Virol (2010) 1.03
Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol (2013) 1.03
Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology (2001) 1.02
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology (2011) 0.97
Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma. J Gen Virol (2007) 0.97
A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology (2005) 0.97
Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther (2012) 0.97
Macrophage tolerance: CD47-SIRP-alpha-mediated signals matter. Nat Immunol (2007) 0.97
Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol (2003) 0.96
Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines. PLoS Pathog (2011) 0.95
Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol (2013) 0.94
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol (2005) 2.38
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology (2013) 2.28
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol (2007) 1.87
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology (2010) 1.65
Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med (2014) 1.64
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med (2014) 1.61
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem (2009) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol (2010) 1.42
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol (2008) 1.36
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Hepatitis C virus entry: molecular biology and clinical implications. Hepatology (2006) 1.34
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2010) 1.31
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 1.22
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol (2012) 1.18
Hepatitis C virus entry. Curr Top Microbiol Immunol (2013) 1.17
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol (2006) 1.17
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology (2008) 1.16
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest (2014) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology (2012) 1.12
Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther (2008) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (2005) 1.11
Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest (2002) 1.11
Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A (2008) 1.09
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology (2008) 1.08
Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med (2010) 1.07
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology (2012) 1.07
Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology (2012) 1.06
Mouse models for the study of HCV infection and virus-host interactions. J Hepatol (2008) 1.05
A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis (2012) 1.05
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One (2009) 1.05
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology (2003) 1.00
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol (2012) 0.99
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology (2014) 0.99